MedTrace Logo

A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain

NCT04976738 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-07-07

No results posted yet for this study

Summary

This is a non-randomised, single arm, open-label study of medical cannabis, Cybis™ 10:25, in participants with chronic back or neck pain in which participants receive escalating doses of Cybis™ 10:25.

Conditions

Interventions

DRUG

Cybis™ 10:25 THC:CBD oil

Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)

Sponsors & Collaborators

  • Cymra Life Sciences

    lead INDUSTRY

Principal Investigators

  • Richard Chye · Cymra Life Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2022-06-15
Completion
2022-06-21

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04976738 on ClinicalTrials.gov